| Name | Title | Contact Details |
|---|
AccuStandard is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ONC Solutions is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sinclair Pharmaceuticals, Ltd. is a Carrollton, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In 1989, Travis Medical was created and incorporated by the Yule family. At that time, it was started with the simple goal to function as a profitable entity while serving the disabled community with dignity and respect. With humble beginnings Travis Medical spent the early portion of the 1990`s operating out of a single suite at their original 34th St. location in the medical district of Austin, TX. With few employees and a single goal, the Yule`s embraced the laid-back culture of Austin and offered an invitation to customers and employees alike to become a member of the extended family. This approach resonated with the medical community in Austin and, with time, Travis Medical began to experience growth.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.